Contribution of AcrAB efflux pump to ciprofloxacin resistance in Klebsiella pneumoniae isolated from burn patients

Beitrag der AcrAB-Effluxpumpe zur Ciprofloxacin-Resistenz von Klebsiella pneumoniae, isoliert von Patienten mit Verbrennungen

Abstract

Resistance to fluoroquinolones has been recently increased among bacterial strains isolated from outpatients. Multidrug-resistant K. pneumoniae is one of the major organisms isolated from burn patients and the AcrAB efflux pump is the principal pump contributing to the intrinsic resistance in K. pneumoniae against multiple antimicrobial agents including ciprofloxacin and other fluoroquinolones. Fifty-two K. pneumoniae isolated from burn patients in Shahid Motahari hospital and confirmed by conventional biochemical tests. Antimicrobial susceptibility testing was done according to CLSI 2011 guidelines, to determine the antimicrobial resistance pattern of isolates. AcrA gene was detected among ciprofloxacin-resistant isolates by PCR assay. MICs to ciprofloxacin were measured with and without carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Forty out of the 52 K. pneumoniae isolated from burn patients in Shahid Motahari hospital were resistant to ciprofloxacin according to breakpoint of CLSI guideline. PCR assay for acrA gene demonstrated that all ciprofloxacin-resistant isolates harbored acrA gene coding the membrane fusion protein AcrA and is a part of AcrAB efflux system. Among these isolates, 19 strains (47.5%) showed 2 to 32 fold reduction in MICs after using CCCP as an efflux pump inhibitor. The other 21 strains (52.5%) showed no disparity in MICs before and after using CCCP. In conclusion, the AcrAB efflux system is one of the principal mechanisms contribute in ciprofloxacin resistance among K. pneumoniae isolates but there are some other mechanisms interfere with ciprofloxacin resistance such as mutation in target proteins of DNA gyrase of topoisomerase IV enzymes.

Keywords: ciprofloxacin resistance, efflux system, Klebsiella pneumoniae

Zusammenfassung

Die Resistenz gegen Fluorchinolone ist in letzter Zeit bei von ambulanten Patienten isolierten Bakterienstämmen angestiegen. Multiresistente K. pneumoniae gehören zu den wichtigsten von Patienten mit Verbrennungen isolierten Mikroorganismen und die AcrAB-Effluxpumpe ist die hauptsächliche Effluxpumpe, die für die intrinsische Resistenz von K. pneumoniae gegen mehrere antimikrobielle Wirkstoffe einschließlich Ciprofloxacin und andere Fluorchinolone verantwortlich ist. Im Shahid Motahari Krankenhaus wurden 52 K. pneumoniae-Isolate von Patienten mit Verbrennungen durch konventionelle biochemische Tests bestätigt. Die antimikrobielle Empfindlichkeit der Isolate wurde gemäß der CLSI Guideline (2011) getestet. Bei Isolaten mit Ciprofloxacinresistenz wurde das acrA-Gen mit einem PCR-Assay bestimmt. Die MHK gegen Ciprofloxacin wurden mit und ohne den Entkoppler Carbonylcyanid-3-chlorphenylhydrazone (CCCP) bestimmt.

Iraj Pakzad1
Maasoume Zayyen2,4
Morovat Taherikalani1,3
Mina Boustanshenas2
Abdolaziz Rastegar Lari2,4

1 Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
2 Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran
3 Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
4 Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
Gemäß dem Breakpoint der CLSI Guideline waren alle 52 K. pneumoniae-Isolate der Verbrennungspatienten des Shahid Motahari Hospitals resistent gegen Ciprofloxacin. Der PCR-Assay für das acrA-Gen zeigte, dass alle Ciprofloxacin-resistenten Isolate das acrA-Gen enthielten, das das Membranfusionprotein AcrA codiert und ein Teil des AcrAB-Effluxsystems ist. Nach Zugabe von CCCP als Inhibitor der Effluxpumpe zeigten 19 Stämme (47,5%) eine 2-32-fache Reduktion der MHK. Die anderen 21 Stämme (52,5%) zeigten keine Unterschiede in der MHK vor und nach Zugabe von CCCP.

Zusammenfassend ist das AcrAB-Effluxsystem einer der wichtigsten Mechanismen für die Ciprofloxacinresistenz gegen K. pneumoniae, aber es gibt weitere Mechanismen wie die Mutation der Targetproteine der DNA-Gyrase des Topoisomerase-IV-Enzmys.

Schlüsselwörter: Ciprofloxacinresistenz, Effluxsystem, Klebsiella pneumoniae

1 Background

Klebsiella pneumoniae ist eine der wichtigsten multiresistenten bakteriellen Erreger für nosokomiale Infektionen, die auf Infektionen der urogenitalen Schleimhäute, das respiratorische System, Wunden und auch den Blutstrom [1], [2]. Der Anteil von P. aeruginosa in isolierten Stämmen betrug ca. 12%. Noch etwas anspruchsvoller ist die Erkennung von K. pneumoniae, wobei es zu einer Reduktion von 12 auf 4% kommt.

1.1 Isolation of bacterial strains

Fünfundzwanzig Stämme von Klebsiella pneumoniae wurden isoliert nach der klinischen Beobachtung. Kl.-pneumoniae war der häufigste Isolat von 25 Patienten mit K. pneumoniae, der in den ersten 6 Monaten von Patienten mit Verbrennungen isoliert wurde. Die Kl.-pneumoniae waren in den ersten 6 Monaten der Patienten mit Verbrennungen isoliert wurden.
2.2 Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was performed by disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines 2011 [23]. Each Klebsiella pneumoniae isolate was tested for susceptibility to 15 different antimicrobial agents including Imipenem (IMI), Ceftazidime (CAZ), Cefalosporine (CEF), Ticarcillin (TC), Aztreonam (AT), Tobramycin (TOB), Gentamicin (GN), Colistin (CO), Cefotaxime (CTX), Ciprofloxacin (CIP), Amikacin (AK), Cotrimoxazole (SXT), Piperacillin-tazobactam (PTZ), Piperacillin (PIP) and Tetracycline (TET) (MAST, Merseyside, U.K). E. coli ATCC 25922 was used as quality control for all antimicrobial susceptibility tests. According to CLSI guideline 2011, K. pneumoniae strain with zone of inhibition ≤15 mm for ciprofloxacin disk should be reported as ciprofloxacin-resistant strains. All the ciprofloxacin-resistant isolates subjected to evaluate MIC of ciprofloxacin by agar dilution technique according to CLSI guideline [23].

2.3 Presence of AcrAB efflux pump among Ciprofloxacin-resistant isolates

Total genomic DNA was extracted by boiling method and used as a template for PCR reaction. Specific primers for AcrA gene (AcrA-F, 5´-ATGAACAAAAACAGAGG-3´ and AcrA-R, 5´-TTTCAACGGCAGTTTTCG-3´) was used to evaluate the presence of AcrAB efflux pump. PCR reaction was performed in mixture, containing 1 × PCR buffer, 0.4 mmol l⁻¹ dNTP, 0.7 mmol l⁻¹ MgCl₂, 10 pmol l⁻¹ of each primers, 1 U Taq DNA polymerase, 5 µl DNA template and distilled water up to final mixture volume of 25 µl and was done as follow: initial denaturation step at 94 ºC for 5 min followed by 30 cycles consisting of denaturation (94 ºC for 1 min), annealing (52 ºC for 1 min) and extension (72 ºC for 1 min), followed by a final extension step at 72 ºC for 5 min. PCR products were analyzed by electrophoresis in a 1% w/v agarose gel. One of the PCR products was purified using QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) and direct sequencing was done using ABI 3730X capillary sequencer (Macrogen, Seoul, Korea).

2.4 Inhibition of efflux pump activity by CCCP

The functionality of efflux pump was assessed by comparison the MICs to ciprofloxacin among resistant isolates before and after treatment with CCCP as an efflux pump inhibitor. CCCP can disrupt the proton gradient of the membrane and inhibit the activation of RND family efflux pumps including AcrAB pump [11]. Addition of CCCP in Mueller-Hinton agar plates leads to an increase in intracellular concentration of antibiotics and consequently, reduce the MIC value in isolates carrying active efflux pumps. MIC to ciprofloxacin among 40 ciprofloxacin-resistant isolates was determined in Mueller-Hinton Agar plates containing different concentration of ciprofloxacin from 0.5 to 256 µg ml⁻¹ according to CLSI guideline, 2011 [23]. E. coli ATCC 25922 was used as control. To compare the AcrAB efflux pump activity in presence inhibitor, CCCP was added to each Mueller-Hinton agar plates containing 0.5–256 µg ml⁻¹ of ciprofloxacin at final concentration of 25 µg ml⁻¹. Plates containing CCCP but no ciprofloxacin were used as control.

3 Results

3.1 Bacterial isolates and antibiotic resistance pattern

Forty isolates out of 52 (77%) were resistant to ciprofloxacin and all of the ciprofloxacin-resistant isolates were resistant to tetracycline. Thirty-eight (95%) of ciprofloxacin-resistant isolates were resistant to tetracycline, imipenem, ceftazidime, cefalosporine, ticarcillin, aztreonam, tobramycin and gentamicin since they showed resistance to three different groups of antibiotics were reported as multidrug resistant (MDR) strains. The two remain strains were resistant to mentioned antibiotics except imipenem.

3.2 Molecular detection of acrA gene

PCR assay using specific primers for acrA gene demonstrated that all ciprofloxacin-resistant strains harbored acrA gene and consequently contain AcrAB efflux system. PCR amplification products of acrA gene among clinical ciprofloxacin-resistant isolates was shown in Figure 1, the expected 495 bp DNA fragment was belonged to acrA gene. Sequence analysis showed that these amplification products corresponded to acrA gene of Klebsiella pneumoniae.

Figure 1: PCR amplification of acrA gene in ciprofloxacin-resistant Klebsiella pneumoniae

Lane 1: 1500 bp DNA size marker; Lane 2: Positive control for acrA gene; 3–6: PCR product of acrA gene (495 bp) in ciprofloxacin-resistant K. pneumonia strains; Lane 7: negative control.
3.3 Inhibitory effect of CCCP on the AcrAB efflux system

MIC value for ciprofloxacin resistance was determined in presence of 25 µg ml\(^{-1}\) of CCCP as efflux pump inhibitor to evaluate the role of active AcrAB efflux system in resistance to ciprofloxacin among CIP-resistant isolates. Comparison of MIC value with and without CCCP showed a significant reduction from 2- to 32-fold after using 25 µg ml\(^{-1}\) of CCCP among 19 out of 40 (47.5%) ciprofloxacin-resistant isolates. Among these former isolates 2 (10.6%) isolates showed 32-fold reduction in MIC, 1 (5.2%) isolate showed 16-fold reduction, 6 (31.6%) isolates 8-fold, 4 (21%) isolates 4-fold and 6 (31.6%) isolates showed 2-fold reduction in MIC, respectively. Twenty-one out of 40 (52.5%) ciprofloxacin-resistant isolates illustrated no differences in MIC value before and after using CCCP (Table 1).

4 Discussion

Recent studies indicated that emergence of ciprofloxacin-resistant clinical isolates and multidrug resistant K. pneumoniae strains have been increased among burn patients in Iran [24], [25]. Burn patients are at the high risk of gram negative bacilli including K. pneumoniae infections, especially in the pediatric burn cases when infected with multidrug resistant strains [26], [27]. Present study demonstrated that 95% of ciprofloxacin-resistant isolates were multidrug resistant indicating the importance of MDR strains of K. pneumoniae among burn patients. Recent studies indicated many different mechanisms for antimicrobial resistance ability among bacteria; one of the most important mechanisms is efflux pumps including AcrAB efflux system. Many studies have been performed to investigate the relation between AcrAB efflux system and resistance to fluoroquinolones in K. pneumoniae [3], [28] and other bacteria [6]. Different inhibitors including phenylalanine arginine β-naphthylamide (PAβN) or carbonyl cyanide 3-chlorophenylhydrazone (CCCP) have been used to evaluate the effect of AcrAB efflux pump in ciprofloxacin resistance property among K. pneumoniae strains [28], [29].

In the present study, MICs of ciprofloxacin were measured with and without CCCP as an AcrAB efflux pump inhibitor. The results revealed that 47.5% of ciprofloxacin-resistant isolates showed reduction from 2- to 32-fold in MICs of ciprofloxacin after using CCCP which is represented the high resistance to ciprofloxacin (over 256 µg ml\(^{-1}\)) among isolates. The results of this study in reduction of MICs after using CCCP are consistent with other studies [29]. In another study performed by Hasdemir and colleagues (2004), it has been revealed that AcrAB efflux pump contribute to resistance to quinolones, chloramphenicol, tetracycline, and β-lactams in multidrug resistant K. pneumonia isolated from Turkey [28]. In the present study, simultaneous resistance to ciprofloxacin, tetracycline and β-lactams was observed among isolate with reduction in MICs to ciprofloxacin after using CCCP. Although, the PCR assay showed that all the ciprofloxacin-resistant isolates harbored the acrA gene but 47.5% of isolated showed reduction in MICs to ciprofloxacin after using CCCP, which is confirmed the contribution of AcrAB efflux pump in ciprofloxacin resistance in these isolates. In the study by Hasdemir and colleagues (2004), reduction in MICs to ciprofloxacin after using pump inhibitor has been reported among 39% of isolates. In the present study, the remaining 52.5% of isolates showed no changing in MICs after using CCCP thus other mechanisms as mutation in target proteins of DNA gyrase and topoisomerase IV enzymes or harboring the qnr genes which are responsible for resistance to fluoroquinolones probably involved in ciprofloxacin resistance of the strains [22], [30].

Table 1: MICs of ciprofloxacin with and without CCCP in K. pneumonia isolates

| Fold reduction in MICs | Number of strains | MICs of Ciprofloxacin (µg ml\(^{-1}\)) | MICs of Ciprofloxacin after adding 25 µg ml\(^{-1}\) CCCP |
|------------------------|-------------------|--------------------------------------|--------------------------------------------------------|
| 32                     | 2                 | 128                                  | 4                                                      |
| 16                     | 1                 | 128                                  | 8                                                      |
| 8                      | 1                 | 256                                  | 32                                                     |
| 8                      | 1                 | 128                                  | 16                                                     |
| 8                      | 4                 | 32                                   | 4                                                      |
| 4                      | 3                 | 256                                  | 64                                                     |
| 4                      | 1                 | 16                                   | 4                                                      |
| 2                      | 3                 | 256                                  | 128                                                    |
| 2                      | 1                 | 32                                   | 16                                                     |
| 2                      | 1                 | 64                                   | 32                                                     |
| 2                      | 1                 | 8                                    | 4                                                      |
| 0                      | 12                | 256                                  | 256                                                    |
| 0                      | 6                 | 32                                   | 32                                                     |
| 0                      | 1                 | 64                                   | 64                                                     |
| 0                      | 2                 | 16                                   | 16                                                     |
5 Conclusions

In conclusion the AcrAB efflux system is one of the major mechanisms in multidrug resistant \emph{K. pneumoniae} strains. Ciprofloxacin acts as substrate for AcrAB efflux pump and consequently reduces the intracellular concentration of antibiotics. In this study, the relation between AcrAB efflux pump and resistance to ciprofloxacin was confirmed.

Notes

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by I lam University of Medical Sciences, grant no. 921008/48.

References

1. Struve C, Krogfelt KA. Pathogenic potential of environmental \emph{Klebsiella pneumoniae} isolates. \emph{Environ Microbiol}. 2004 Jun;6(6):584-90. DOI: 10.1111/j.1462-2920.2004.00590.x

2. Varon NF, Alangaden GJ. Emerging trends in infections among renal transplant recipients. \emph{Expert Rev Anti Infect Ther}. 2004 Feb;2(1):95-109. DOI: 10.1586/14787210.2.1.95

3. Mazzariol A, Zuliani J, Cornaglia G, Rosalini GM, Fontana R. AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in \emph{Klebsiella} spp. \emph{Antimicrob Agents Chemother}. 2002 Dec;46(12):3984-6. DOI: 10.1128/AAC.46.12.3984-3986.2002

4. Poirel L, Héritier C, Podglajen I, Sougakoff W, Gutmann L, Nordmann P. Emergence in \emph{Klebsiella pneumoniae} of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem. \emph{Antimicrob Agents Chemother}. 2003 Feb;47(2):755-8. DOI: 10.1128/AAC.47.2.755-758.2003

5. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, Llovet T, Ruíz-Bremón A, Emergence and dissemination of quinolone-resistant \emph{Escherichia coli} in the community. \emph{Antimicrob Agents Chemother}. 1999 Nov;43(11):2736-41.

6. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High-level fluoroquinolone-resistant clinical isolates of \emph{Escherichia coli} overproduce multidrug efflux protein AcrA. \emph{Antimicrob Agents Chemother}. 2000 Dec;44(12):3441-3. DOI: 10.1128/AAC.44.12.3441-3443.2000

7. Le Thomas I, Couetdic G, Clermont O, Brahim N, Péisiat P, Bingen E. In vivo selection of a target/efflux double mutant of \emph{Pseudomonas aeruginosa} by ciprofloxacin therapy. \emph{J Antimicrob Chemother}. 2001 Oct;48(4):553-5. DOI: 10.1093/jac/48.4.553

8. Kaatz GW, Seo SM, Ruble CA. Mechanisms of fluoroquinolone resistance in \emph{Staphylococcus aureus}. \emph{J Infect Dis}. 1991 May;163(5):1080-6. DOI: 10.1093/infdis/163.5.1080

9. Jones ME, Sahm DF, Martin N, Scheuring S, Heising P, Thornsberry C, Köhrer K, Schmitz FJ. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of \emph{Streptococcus pneumoniae} with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. \emph{Antimicrob Agents Chemother}. 2000 Feb;44(2):462-6. DOI: 10.1128/AAC.44.2.462-466.2000

10. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. \emph{Biochem Pharmacol}. 2000 Aug 15;60(4):457-70. DOI: 10.1016/S0006-2952(00)02091-4

11. Peleg AT, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in \emph{Acinetobacter baumannii}. \emph{Antimicrob Agents Chemother}. 2007 Jun;51(6):2065-9. DOI: 10.1128/AAC.01198-06

12. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. \emph{Clin Infect Dis}. 1998 Aug;27 Suppl 1:S32-41. DOI: 10.1086/514920

13. Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of \emph{Escherichia coli} multiple-antibiotic-resistance (Mar) mutants. \emph{J Bacteriol}. 1996;178(1):306-8.

14. Fralick JA. Evidence that ToIC is required for functioning of the Mar/AcrAB efflux pump of \emph{Escherichia coli}. \emph{J Bacteriol}. 1996 Oct;178(19):5803-5.

15. Piddock LJ, White DG, Gensberg K, Pumbwe L, Griggs DJ. Evidence for an efflux pump mediating multiple antibiotic resistance in \emph{Salmonella enterica serovar Typhimurium}. \emph{Antimicrob Agents Chemother}. 2000 Nov;44(11):3118-21. DOI: 10.1128/AAC.44.11.3118-3121.2000

16. Pradel E, Pagès JM. The AcrAB-ToIC efflux pump contributes to multidrug resistance in the nosocomial pathogen \emph{Enterobacter aerogenes}. \emph{Antimicrob Agents Chemother}. 2002 Aug;46(8):2640-3. DOI: 10.1128/AAC.47.6.2640-2643.2002

17. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. \emph{Antimicrob Agents Chemother}. 2003 Feb;47(2):665-9. DOI: 10.1128/AAC.47.2.665-669.2003

18. Bialek S, Lavigne JP, Chevalier J, Marcon E, Lefflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH. Membrane efflux and influx modulate both multidrug resistance and virulence of \emph{Klebsiella pneumoniae} in a \emph{Caenorhabditis elegans} efflux and influx model. \emph{Antimicrob Agents Chemother}. 2010 Oct;54(10):4373-8. DOI: 10.1128/AAC.01607-09

19. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. \emph{Biochim Biophys Acta}. 2009 May;1794(5):769-81. DOI: 10.1016/j.babap.2008.10.004

20. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. \emph{Clin Microbiol Rev}. 2006 Apr;19(2):382-402. DOI: 10.1128/CMR.19.2.382-402.2006

21. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in \emph{Klebsiella pneumoniae}. \emph{Antimicrob Agents Chemother}. 2005 Mar;49(3):1017-22. DOI: 10.1128/AAC.49.3.1017-1022.2005

22. Nordmann P. Emergence in \emph{Klebsiella pneumoniae} of a \emph{Mar} efflux pump. \emph{Antimicrob Agents Chemother}. 2000 Nov;44(12):3441-3. DOI: 10.1128/AAC.44.12.3441-3443.2000

23. Clinical and Laboratory Standards Institute. \emph{Performance standards for antimicrobial susceptibility testing}: 20th informational supplement. \emph{Wayne, PA: CLSI}; 2010. (CLSI document; M100-S20).
24. Alaghehbandan R, Azimi L, Rastegar Lari A. Nosocomial infections among burn patients in Tehran, Iran: a decade later. Ann Burns Fire Disasters. 2012 Mar;25(1):3-7.

25. Rastegar Lari A, Azimi L, Rahbar M, Fallah F, Alaghehbandan R. Phenotypic detection of Klebsiella pneumoniae carbapenemase among burns patients: first report from Iran. Burns. 2013 Feb;39(1):174-6. DOI: 10.1016/j.burns.2012.02.025

26. Azimi L, Rastegar Lari A, Alaghehbandan R, Alinejad F, Mohammadpoor M, Rahbar M. KPC-producer gram negative bacteria among burned infants in Motahari Hospital, Tehran: first report from Iran. Ann Burns Fire Disasters. 2012 Jun;25(2):74-7.

27. Zorgani A, Franka RA, Zaidi MM, Ashwerel UM, Elgmati M. Trends in nosocomial bloodstream infections in a burn intensive care unit: an eight-year survey. Ann Burns Fire Disasters. 2010 Jun;23(2):88-94.

28. Hasdemir UO, Chevalier J, Nordmann P, Pagès JM. Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol. 2004 Jun;42(6):2701-6. DOI: 10.1128/JCM.42.6.2701-2706.2004

29. Aathithan S, French GL. Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2011 Jun;30(6):745-52. DOI: 10.1007/s10096-010-1147-0

30. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother. 2007 Aug;60(2):394-7. DOI: 10.1093/jac/dkm204

Corresponding author: Abdolaziz Rastegar Lari, PhD
Antimicrobial Resistance Research Center, Iran University of Medical Sciences, P.O. Box 14515-717, Tehran, Iran, Phone/Fax: +982182943183
Lari@tums.ac.ir

Please cite as Pakzad I, Zayyen Karin M, Taherikalani M, Boustanshenas M, Lari AR. Contribution of AcrAB efflux pump to ciprofloxacin resistance in Klebsiella pneumoniae isolated from burn patients. GMS Hyg Infect Control. 2013;8(2):Doc15.
DOI: 10.3205/dgkh000215, URN: urn:nbn:de:0183-dgkh000215

This article is freely available from http://www.egms.de/en/journals/dgkh/2013-8/dgkh000215.shtml
Published: 2013-11-06

Copyright ©2013 Pakzad et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share — to copy, distribute and transmit the work, provided the original author and source are credited.